Akari Therapeutics to Offer 1.14M ADSs and Warrants, Signaling Massive Dilution
AKTX sits 89% above its 52-week low of $3.25 on light trading volume (0.1× avg).
Summary
Akari Therapeutics announced an offering of up to 1.14 million American Depositary Shares (ADSs), 1.14 million Series H Warrants, and 1.14 million Series I Warrants. This news provides the specific, highly dilutive quantities for the "best-efforts" offering that was registered via an S-1 filing earlier today. Given Akari's small market capitalization, an offering of 1.14 million ADSs at the current stock price would represent a potential dilution of nearly 94% of the company's current market value. This substantial dilution is a critical event that will likely have a severe negative impact on the stock price and existing shareholder value. Traders will closely monitor the market's reaction and the final terms of this offering.
At the time of this announcement, AKTX was trading at $6.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $3.25 to $56.80. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.